Carasent AB (publ) (APXZF) Q2 2026 Earnings Call Transcript

Carasent reported highly recurring revenue of >90% alongside 15% organic ARR growth and 110% net revenue retention in Q2 2026. The company also completed the acquisition of Infosolutions and grew sign-up implemented from SEK 4 million in Q1 to SEK 6 million in Q2, with most new sales tied to Webdoc. Overall, the mix of strong retention, accelerating ARR, and completed M&A points to continued momentum rather than near-term earnings stress.

Analysis

This reads more like a quality-of-business confirmation than a step-change story: the core asset is recurring clinic software with enough retention to support multiple expansion, but the real value driver is cross-sell into installed accounts rather than headline ARR alone. If Infosolutions truly expands distribution or product depth, the second-order benefit is lower CAC and higher wallet share, which should show up first in billings and deferred revenue before it meaningfully changes reported EBITDA.

Competitive dynamics look favorable for the few vertical SaaS vendors with embedded workflows. A stronger Carasent can pressure smaller point-solution vendors and local legacy incumbents, because healthcare IT buying is sticky once integrated into scheduling, documentation, and billing. The risk is that this also raises integration complexity; in this segment, one bad implementation quarter can create elongated sales cycles and slow conversion of sign-ups into revenue even when top-line activity looks healthy.

Near term, the stock should trade on whether the market believes the ARR/NRR durability is real enough to justify a higher EV/ARR multiple versus other Nordic software names. Over 1-3 months, the main catalyst is guidance follow-through and evidence that acquired assets are accretive rather than dilutive to margin. Over 6-18 months, the thesis only works if recurring revenue keeps compounding without a step-up in churn, bad debt, or implementation costs.

The contrarian view is that investors may be underweighting integration risk and overpaying for reported growth in a niche where procurement is lumpy and customer concentration can mask weakness. If post-close cross-sell stalls, or if organic ARR decelerates below low-teens while NRR slips under 105%, the re-rating case likely fails. For a small-cap name like this, liquidity and execution matter as much as the operating metrics.

Key Decisions for Investors

• Maintain a tactical long bias in TSTS only on pullbacks after the print; the setup is better as a 1-3 month re-rating trade than a chase into strength, with upside tied to confirmation that acquisition synergies are real.
• Use a pair trade if accessible: long TSTS / short a slower-growing vertical SaaS or healthcare software proxy on valuation, targeting multiple compression in the weaker name if Carasent proves its growth is durable over the next 1-2 quarters.
• Set a watch item on next-quarter billings, ARR and churn rather than revenue alone; if organic ARR falls below low-teens or NRR drops under 105%, treat that as a thesis break and reduce exposure.
• If options are liquid enough, consider a limited-risk call spread in TSTS for the next earnings cycle; the payoff is tied to a rerating on integration credibility, not a large fundamental inflection.
• Avoid assuming the acquisition is immediately accretive; wait for evidence on margin bridge and customer retention before adding size, since the main downside is integration slippage rather than demand collapse.